Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

Azita H Talasaz; Parham Sadeghipour; Hessam Kakavand; Maryam Aghakouchakzadeh; Elaheh Kordzadeh-Kermani; Benjamin W Van Tassell; Azin Gheymati; Hamid Ariannejad; Seyed Hossein Hosseini; Sepehr Jamalkhani; Michelle Sholzberg; Manuel Monreal; David Jimenez; Gregory Piazza; Sahil A Parikh; Ajay J Kirtane; John W Eikelboom; Jean M Connors; Beverley J Hunt; Stavros V Konstantinides; Mary Cushman; Jeffrey I Weitz; Gregg W Stone; Harlan M Krumholz; Gregory Y H Lip; Samuel Z Goldhaber; Behnood Bikdeli

doi:10.1016/j.jacc.2021.02.035

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

Azita H Talasaz, Parham Sadeghipour, Hessam Kakavand, Maryam Aghakouchakzadeh, Elaheh Kordzadeh-Kermani, Benjamin W Van Tassell, Azin Gheymati, Hamid Ariannejad, Seyed Hossein Hosseini, Sepehr Jamalkhani, Michelle Sholzberg, Manuel Monreal, David Jimenez, Gregory Piazza, Sahil A Parikh, Ajay J Kirtane, John W Eikelboom, Jean M Connors, Beverley J Hunt, Stavros V KonstantinidesMary Cushman, Jeffrey I Weitz, Gregg W Stone, Harlan M Krumholz, Gregory Y H Lip, Samuel Z Goldhaber, Behnood Bikdeli

Research output: Contribution to journal › Review article › peer-review

144 Citations (Scopus)

Abstract

Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.

Original language	English
Journal	Journal of the American College of Cardiology
Volume	77
Issue number	15
Pages (from-to)	1903-1921
Number of pages	19
ISSN	0735-1097
DOIs	https://doi.org/10.1016/j.jacc.2021.02.035
Publication status	Published - 20 Apr 2021

Keywords

COVID-19
RCT
anticoagulant
antiplatelet
clinical trial
thrombosis

Access to Document

10.1016/j.jacc.2021.02.035

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963001/pdf/main.pdf

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Talasaz, A. H., Sadeghipour, P., Kakavand, H., Aghakouchakzadeh, M., Kordzadeh-Kermani, E., Van Tassell, B. W., Gheymati, A., Ariannejad, H., Hosseini, S. H., Jamalkhani, S., Sholzberg, M., Monreal, M., Jimenez, D., Piazza, G., Parikh, S. A., Kirtane, A. J., Eikelboom, J. W., Connors, J. M., Hunt, B. J., ... Bikdeli, B. (2021). Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 77(15), 1903-1921. Advance online publication. https://doi.org/10.1016/j.jacc.2021.02.035

@article{4fc75edaf137462d9d70f4b8fb2a0e43,

title = "Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review",

abstract = "Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.",

keywords = "COVID-19, RCT, anticoagulant, antiplatelet, clinical trial, thrombosis",

author = "Talasaz, {Azita H} and Parham Sadeghipour and Hessam Kakavand and Maryam Aghakouchakzadeh and Elaheh Kordzadeh-Kermani and {Van Tassell}, {Benjamin W} and Azin Gheymati and Hamid Ariannejad and Hosseini, {Seyed Hossein} and Sepehr Jamalkhani and Michelle Sholzberg and Manuel Monreal and David Jimenez and Gregory Piazza and Parikh, {Sahil A} and Kirtane, {Ajay J} and Eikelboom, {John W} and Connors, {Jean M} and Hunt, {Beverley J} and Konstantinides, {Stavros V} and Mary Cushman and Weitz, {Jeffrey I} and Stone, {Gregg W} and Krumholz, {Harlan M} and Lip, {Gregory Y H} and Goldhaber, {Samuel Z} and Behnood Bikdeli",

year = "2021",

month = apr,

day = "20",

doi = "10.1016/j.jacc.2021.02.035",

language = "English",

volume = "77",

pages = "1903--1921",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier",

number = "15",

}

Talasaz, AH, Sadeghipour, P, Kakavand, H, Aghakouchakzadeh, M, Kordzadeh-Kermani, E, Van Tassell, BW, Gheymati, A, Ariannejad, H, Hosseini, SH, Jamalkhani, S, Sholzberg, M, Monreal, M, Jimenez, D, Piazza, G, Parikh, SA, Kirtane, AJ, Eikelboom, JW, Connors, JM, Hunt, BJ, Konstantinides, SV, Cushman, M, Weitz, JI, Stone, GW, Krumholz, HM, Lip, GYH, Goldhaber, SZ & Bikdeli, B 2021, 'Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review', Journal of the American College of Cardiology, vol. 77, no. 15, pp. 1903-1921. https://doi.org/10.1016/j.jacc.2021.02.035

TY - JOUR

T1 - Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

T2 - JACC State-of-the-Art Review

AU - Talasaz, Azita H

AU - Sadeghipour, Parham

AU - Kakavand, Hessam

AU - Aghakouchakzadeh, Maryam

AU - Kordzadeh-Kermani, Elaheh

AU - Van Tassell, Benjamin W

AU - Gheymati, Azin

AU - Ariannejad, Hamid

AU - Hosseini, Seyed Hossein

AU - Jamalkhani, Sepehr

AU - Sholzberg, Michelle

AU - Monreal, Manuel

AU - Jimenez, David

AU - Piazza, Gregory

AU - Parikh, Sahil A

AU - Kirtane, Ajay J

AU - Eikelboom, John W

AU - Connors, Jean M

AU - Hunt, Beverley J

AU - Konstantinides, Stavros V

AU - Cushman, Mary

AU - Weitz, Jeffrey I

AU - Stone, Gregg W

AU - Krumholz, Harlan M

AU - Lip, Gregory Y H

AU - Goldhaber, Samuel Z

AU - Bikdeli, Behnood

PY - 2021/4/20

Y1 - 2021/4/20

N2 - Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.

AB - Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.

KW - COVID-19

KW - RCT

KW - anticoagulant

KW - antiplatelet

KW - clinical trial

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85102860031&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2021.02.035

DO - 10.1016/j.jacc.2021.02.035

M3 - Review article

C2 - 33741176

SN - 0735-1097

VL - 77

SP - 1903

EP - 1921

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 15

ER -